| HealthPartners | Natalizumab (Tysabri®, Tyruko®) | 2025-07-01 |
| HealthPartners | Natalizumab (Tysabri®, Tyruko®) - Minnesota Health | 2025-07-01 |
| HealthPartners | Neonatal Fc receptor antagonists (Vyvgart®, Vyvgart® | 2025-07-01 |
| HealthPartners | Ocrelizumab (Ocrevus®) and Ocrelizumab hya-ocsq | 2025-07-01 |
| HealthPartners | Ocrelizumab (Ocrevus®) – Minnesota Health Care | 2025-07-01 |
| HealthPartners | Onasemnogene abeparvovec-xioi (Zolgensma®) – | 2025-07-01 |
| HealthPartners | Oncology - ado-trastuzumab emtansine (Kadcyla®), | 2025-07-01 |
| HealthPartners | Oncology - ado-trastuzumab emtansine (Kadcyla®), | 2025-07-01 |
| HealthPartners | Oncology - daratumumab and daratumumab | 2025-07-01 |
| HealthPartners | Oncology - daratumumab and daratumumab | 2025-07-01 |